Novartis Raises $11 Billion in Multi-Tranche U.S. Bond Offering
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Novartis ( (NVS) ) is now available.
On March 18, 2026, Novartis AG filed a Form 6-K in the United States reporting a major U.S. dollar bond issuance by its financing arm, Novartis Capital Corporation, which is fully and unconditionally guaranteed by the parent company. The transaction totals $11 billion across floating-rate notes and multiple fixed-rate tranches maturing between 2029 and 2056, underscoring Novartis’s active use of long-dated debt financing and strengthening its capital structure for future corporate needs.
The filing, which follows a terms agreement dated March 16, 2026 with a syndicate of underwriters led by BNP Paribas, Citigroup, Deutsche Bank, J.P. Morgan and Mizuho, incorporates the bond documentation into an existing shelf registration. By locking in sizable funding across the curve, Novartis enhances its financial flexibility and maintains its presence in the U.S. investment-grade bond market, an important channel for its long-term funding strategy.
The most recent analyst rating on (NVS) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.
Spark’s Take on NVS Stock
According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.
Score is driven primarily by strong underlying financial quality (high margins and strong free cash flow) and a bullish technical trend. The key constraints are management’s softer 2026 profit outlook amid significant LOE/generic headwinds and a valuation that looks reasonable rather than clearly discounted.
To see Spark’s full report on NVS stock, click here.
More about Novartis
Novartis AG is a Switzerland-based global pharmaceutical company focused on developing, manufacturing and marketing innovative prescription medicines. Through its financing subsidiary Novartis Capital Corporation, the group also regularly accesses international debt markets to support its operations and strategic investments in the healthcare sector.
Average Trading Volume: 2,276,711
Technical Sentiment Signal: Buy
Current Market Cap: $295.1B
For a thorough assessment of NVS stock, go to TipRanks’ Stock Analysis page.
